Zacks: Brokerages Anticipate Sarepta Therapeutics Inc (SRPT) to Announce -$0.36 Earnings Per Share
Wall Street analysts expect that Sarepta Therapeutics Inc (NASDAQ:SRPT) will report earnings per share of ($0.36) for the current fiscal quarter, according to Zacks Investment Research. Six analysts have provided estimates for Sarepta Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.56). Sarepta Therapeutics posted earnings of ($1.58) per share in the same quarter last year, which suggests a positive year over year growth rate of 77.2%. The business is expected to issue its next earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that Sarepta Therapeutics will report full-year earnings of ($1.17) per share for the current financial year, with EPS estimates ranging from ($3.24) to ($0.68). For the next financial year, analysts forecast that the business will post earnings of ($0.66) per share, with EPS estimates ranging from ($1.58) to $0.20. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Sarepta Therapeutics.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.86) by $0.66. Sarepta Therapeutics had a negative return on equity of 35.62% and a negative net margin of 103.87%. The firm had revenue of $45.95 million for the quarter, compared to analysts’ expectations of $41.29 million. During the same quarter in the previous year, the company earned ($0.95) earnings per share.
SRPT has been the topic of several recent analyst reports. Goldman Sachs Group Inc reissued a “buy” rating and set a $71.00 target price on shares of Sarepta Therapeutics in a report on Friday, October 6th. ValuEngine cut Sarepta Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 2nd. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Sarepta Therapeutics in a report on Monday, September 25th. SunTrust Banks, Inc. reaffirmed a “buy” rating and issued a $56.00 price target on shares of Sarepta Therapeutics in a report on Thursday, September 7th. Finally, Robert W. Baird reaffirmed a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $63.59.
Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $55.46 on Tuesday. Sarepta Therapeutics has a twelve month low of $26.26 and a twelve month high of $57.57. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.44 and a quick ratio of 9.52.
In other Sarepta Therapeutics news, SVP Shamim Ruff sold 10,000 shares of the business’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the transaction, the senior vice president now owns 37,045 shares of the company’s stock, valued at approximately $2,037,475. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Douglas S. Ingram bought 38,138 shares of the business’s stock in a transaction on Wednesday, November 8th. The shares were purchased at an average cost of $52.44 per share, with a total value of $1,999,956.72. Following the transaction, the chief executive officer now owns 420,196 shares in the company, valued at $22,035,078.24. The disclosure for this purchase can be found here. 9.60% of the stock is currently owned by insiders.
Several institutional investors and hedge funds have recently made changes to their positions in SRPT. Jennison Associates LLC raised its position in shares of Sarepta Therapeutics by 103.9% during the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock valued at $51,885,000 after buying an additional 582,894 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in shares of Sarepta Therapeutics during the third quarter valued at about $26,011,000. Voya Investment Management LLC increased its stake in Sarepta Therapeutics by 2,786.1% in the second quarter. Voya Investment Management LLC now owns 568,525 shares of the biotechnology company’s stock valued at $19,165,000 after acquiring an additional 548,826 shares during the period. Gilder Gagnon Howe & Co. LLC increased its stake in Sarepta Therapeutics by 3,599.4% in the third quarter. Gilder Gagnon Howe & Co. LLC now owns 534,087 shares of the biotechnology company’s stock valued at $24,226,000 after acquiring an additional 519,650 shares during the period. Finally, HealthCor Management L.P. increased its stake in Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after acquiring an additional 481,890 shares during the period. 73.84% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dailypolitical.com/2017/11/28/zacks-brokerages-anticipate-sarepta-therapeutics-inc-srpt-to-announce-0-36-earnings-per-share.html.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sarepta Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.